Datapoint: FDA Expands Verzenio’s Breast Cancer Label

The FDA on March 3 expanded Eli Lilly’s Verzenio’s use in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer in patients that have a high risk of recurrence. Patients will no longer require a Ki-67 biomarker test to receive the drug, and will instead be identified based on nodal status, tumor size and grade. Verzenio was first approved as an adjuvant breast cancer therapy in 2021. The CDK4/6 inhibitor currently holds covered or better status for 97% of all insured lives under the pharmacy benefit. 15% of lives have preferred access to Verzenio, growing to 39% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/8/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 24

Datapoint: Priority Health to Acquire Indiana Plan

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today